Publications by authors named "D Hutton"
Article Synopsis
- Respiratory syncytial virus (RSV) leads to significant hospitalizations in infants in the US, prompting recommendations for nirsevimab to prevent RSV in all infants under 8 months and at-risk children up to 19 months during their RSV seasons.* -
- A simulation study found that administering nirsevimab could potentially avoid over 107,000 outpatient visits and 14,000 hospitalizations annually if half of newborns receive it, costing approximately $153,517 per quality-adjusted life year (QALY) saved.* -
- The analysis suggests nirsevimab is cost-effective, particularly for high-risk infants, though the cost-per-QALY can vary widely based on factors like hospitalization costs
Background And Objectives: Respiratory syncytial virus (RSV) commonly causes hospitalization among US infants. A maternal vaccine preventing RSV in infants, RSV bivalent prefusion F maternal vaccine (RSVpreF), was approved by the US Food and Drug Administration and recommended by the Advisory Committee on Immunization Practices. Our objective was to evaluate the health benefits and cost-effectiveness of vaccinating pregnant persons in the United States using RSVpreF.
View Article and Find Full Text PDFThe abscopal effect is a phenomenon wherein localised therapy on the primary tumour leads to regression of distal metastatic growths. Interestingly, various pre-clinical studies utilising sonodynamic therapy (SDT) have reported significant abscopal effects, however, the mechanism remains largely enigmatic. SDT is an emerging non-invasive cancer treatment that uses focussed ultrasound (FUS) and a sonosensitiser to induce tumour cell death.
View Article and Find Full Text PDFBackground: The HIMALAYA trial found that durvalumab plus tremelimumab significantly prolonged progression-free survival and overall survival in patients with unresectable hepatocellular carcinoma (HCC) compared with sorafenib.
Objective: This study aimed to investigate the cost-effectiveness of durvalumab plus tremelimumab compared with sorafenib in the first-line HCC setting.
Design: A Markov model-based cost-effectiveness analysis.